Regeneron Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –
Regeneron Pharmaceuticals Direct Clinical R&D by Quarter
Direct Clinical R&D — EYLEA (2 mg) [legacy through FY22] ($M) ($M)
Regeneron Pharmaceuticals Direct Clinical R&D: $16.3M in Q2 2022, down 39.0% from a year earlier. No newer figure appears in the documents we track.
Where the Q2 2022 figure comes from
“R&D Expenses Table (FY2022Q2): EYLEA | 16.3 | 26.7 | (10.4) | 40.7 | 54.8 | (14.1)”
Source: Form 10-Q (regn-20220630.htm, filed 2022-08-03) ↗
Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses by Clinical Program.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Direct Clinical R&D ($M), quarterly Q1 2019–Q2 2022 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-prog-eylea-leg
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?